This type-2 application is to strengthen and build upon the established U54 Partnership between Morehouse School of Medicine (MSM), Tuskegee University (TU), and the UAB Comprehensive Cancer Center (UABCCC). The Partnership, located in the heart of the Southeast, a region with a large, historically underserved, African American population, has the overall goal of attaining excellence in research focused on elimination of cancer health disparities and on reducing the cancer burden among underserved populations in the region. The partnering institutions possess unique strengths that complement each other in achieving the proposed goal through integrated research, education, and outreach. The primary objectives are to enhance productive cancer research programs, to develop a pipeline of racial/ethnic minority investigators in cancer research at MSM and TU, and to increase the level of involvement of investigators conducting research on cancer disparities at the UAB CCC. The Partnership has four Cores (Administrative, Outreach, Research Education, and Planning & Evaluation); two Full Research Projects; a Pilot Research Project; and two Shared Resources (Bioethics and Biostatistics/Bioinformatics). With these assets and activities, the Partnership will: 1) through the full projects, identify molecular mechanisms and new therapeutic targets for metastatic prostate cancer, which is present at a higher rate in African American men, and, through the pilot project, adapt the current, successful patient navigation program for racial/ethnic minority recruitment at the UAB CCC for implementation at the MSM and Grady Hospital; 2) through the Outreach Core, apply an innovative cancer survivor care plan at MSM, TU, and the UAB CCC by linking community- and health system-based patient navigators and advisors to improve satisfaction with care, and implement culturally appropriate community health education for cancer survivors and caregivers; 3) through the Research Education Core, employ an integrated cancer research education program that involves capacity building and linkages to undergraduate and graduate students and junior faculty, allowing them to pursue careers in cancer research; and 4) provide funding for additional Pilot Research projects. The Planning & Evaluation Core will continually assess/evaluate the outcomes of the cores, research projects, and shared resources. The Bioethics Shared Resource will promote and ensure adherence to bioethical principles and address ethical considerations in relationships between the institutions and between the institutions and communities. The Biostatistics/Bioinformatics Shared Resource will deliver statistical and bioinformatics support for all activities. Together, we will contribute to elimination of cancer health disparities.

Public Health Relevance

This type 2 U54 application is from the existing, successful Partnership between Morehouse School of Medicine (MSM), Tuskegee University (TU), and the UAB Comprehensive Cancer Center (UABCCC), which is committed to elimination of cancer health disparities in racial/ethnic minority and underserved populations in the `Deep South,' particularly among African Americans. By leveraging the distinct yet complementary strengths and resources of this Partnership, rigorous and collaborative transdisciplinary research that encompasses basic biologic, preclinical, clinical, educational, behavioral, social, and community-based programs is proposed to understand the causes for cancer health disparities and to test evidence-based solutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA118623-12
Application #
9358677
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Whitaker, Damiya Eve
Project Start
2005-09-28
Project End
2021-08-31
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
12
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Tuskegee University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
128214178
City
Tuskegee Institute
State
AL
Country
United States
Zip Code
36088
Akintobi, Tabia Henry; Lockamy, Elise; Goodin, Lisa et al. (2018) Processes and Outcomes of a Community-Based Participatory Research-Driven Health Needs Assessment: A Tool for Moving Health Disparity Reporting to Evidence-Based Action. Prog Community Health Partnersh 12:139-147
Angajala, Anusha; Mothershed, Essynce; Davis, Melissa B et al. (2018) Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer. Transl Oncol 12:493-501
Davis, Melissa; Tripathi, Shweta; Hughley, Raymond et al. (2018) AR negative triple negative or ""quadruple negative"" breast cancers in African American women have an enriched basal and immune signature. PLoS One 13:e0196909
Angajala, Anusha; Lim, Sangbin; Phillips, Joshua B et al. (2018) Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism. Front Immunol 9:1605
Abisoye-Ogunniyan, Abisola; Lin, Huxian; Ghebremedhin, Anghesom et al. (2018) Transcriptional repressor Kaiso promotes epithelial to mesenchymal transition and metastasis in prostate cancer through direct regulation of miR-200c. Cancer Lett 431:1-10
Mukherjee, Angana; Hollern, Daniel P; Williams, Oluwasina G et al. (2018) A Review of FOXI3 Regulation of Development and Possible Roles in Cancer Progression and Metastasis. Front Cell Dev Biol 6:69
Ahmed, Md Shakir Uddin; Salam, Ahmad Bin; Yates, Clayton et al. (2017) Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer. Int J Nanomedicine 12:6973-6984
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 141 publications